checkAd

     193  0 Kommentare TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138 - Seite 4

    For more information, please contact:

    Lesen Sie auch

    TransCode Therapeutics, Inc.
    Alan Freidman, VP Investor Relations
    alan.freidman@transcodetherapeutics.com 



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138 - Seite 4 Suggests potential to improve survival outcomes in patients with GBMBOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA …